

Sandra Tuybaerts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7782011/publications.pdf>

Version: 2024-02-01

47
papers

2,447
citations

218381
26
h-index

243296
44
g-index

47
all docs

47
docs citations

47
times ranked

3114
citing authors

#	ARTICLE	IF	CITATIONS
1	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	326
2	Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules. <i>Journal of Immunology</i> , 2004, 172, 6649-6657.	0.4	182
3	CD83 expression on dendritic cells and T cells: Correlation with effective immune responses. <i>European Journal of Immunology</i> , 2007, 37, 686-695.	1.6	173
4	Enhancing the T-cell Stimulatory Capacity of Human Dendritic Cells by Co-electroporation With CD40L, CD70 and Constitutively Active TLR4 Encoding mRNA. <i>Molecular Therapy</i> , 2008, 16, 1170-1180.	3.7	166
5	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 1513-1537.	2.0	149
6	Single-Step Antigen Loading and Activation of Dendritic Cells by mRNA Electroporation for the Purpose of Therapeutic Vaccination in Melanoma Patients. <i>Clinical Cancer Research</i> , 2009, 15, 3366-3375.	3.2	149
7	Therapeutic Vaccination With an Autologous mRNA Electroporated Dendritic Cell Vaccine in Patients With Advanced Melanoma. <i>Journal of Immunotherapy</i> , 2011, 34, 448-456.	1.2	124
8	Generation of large numbers of dendritic cells in a closed system using Cell Factories [®] . <i>Journal of Immunological Methods</i> , 2002, 264, 135-151.	0.6	104
9	Mapping the immunosuppressive environment in uterine tumors: implications for immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 545-557.	2.0	102
10	Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. <i>Gene Therapy</i> , 2005, 12, 772-782.	2.3	85
11	Side-by-Side Comparison of Lentivirally Transduced and mRNA-Electroporated Dendritic Cells: Implications for Cancer Immunotherapy Protocols. <i>Molecular Therapy</i> , 2004, 10, 768-779.	3.7	78
12	The immune system in the normal endometrium and implications for endometrial cancer development. <i>Journal of Reproductive Immunology</i> , 2015, 109, 7-16.	0.8	76
13	Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. <i>Journal of Leukocyte Biology</i> , 2007, 82, 93-105.	1.5	57
14	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>Oncotarget</i> , 2022, 11, .	2.1	54
15	Melan-A/MART-1-Specific CD4 T Cells in Melanoma Patients: Identification of New Epitopes and Ex Vivo Visualization of Specific T Cells by MHC Class II Tetramers. <i>Journal of Immunology</i> , 2006, 177, 6769-6779.	0.4	48
16	Induction of Influenza Matrix Protein 1 and MelanA-specific T lymphocytes in vitro using mRNA-electroporated dendritic cells. <i>Cancer Gene Therapy</i> , 2003, 10, 696-706.	2.2	46
17	PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer. <i>BMC Cancer</i> , 2019, 19, 506.	1.1	46
18	Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide. <i>Cancer Research</i> , 2003, 63, 5587-94.	0.4	45

#	ARTICLE	IF	CITATIONS
19	Wilms' Tumor Gene 1 (WT1)-loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial. <i>Anticancer Research</i> , 2013, 33, 5495-500.	0.5	37
20	Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. <i>Anticancer Research</i> , 2013, 33, 3855-9.	0.5	36
21	Potential Therapeutic Targets in Uterine Sarcomas. <i>Sarcoma</i> , 2015, 2015, 1-14.	0.7	34
22	A Phase 2 Study to Assess the Immunomodulatory Capacity of a Lecithin-based Delivery System of Curcumin in Endometrial Cancer. <i>Frontiers in Nutrition</i> , 2018, 5, 138.	1.6	32
23	Activation of Monocytes via the CD14 Receptor Leads to the Enhanced Lentiviral Transduction of Immature Dendritic Cells. <i>Human Gene Therapy</i> , 2004, 15, 562-573.	1.4	31
24	Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. <i>Gene Therapy</i> , 2006, 13, 1027-1036.	2.3	30
25	The Effects of Cannabidiol and Prognostic Role of TRPV2 in Human Endometrial Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5409.	1.8	29
26	The Controversial Role of PD-1 and Its Ligands in Gynecological Malignancies. <i>Frontiers in Oncology</i> , 2019, 9, 1073.	1.3	28
27	Dendritic cells differentiated in the presence of IFN- γ and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. <i>Journal of Leukocyte Biology</i> , 2005, 78, 898-908.	1.5	27
28	Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. <i>Journal of Immunological Methods</i> , 2012, 377, 23-36.	0.6	24
29	Contribution of Aging, Obesity, and Microbiota on Tumor Immunotherapy Efficacy and Toxicity. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3586.	1.8	18
30	Intratumoral Combinatorial Administration of CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Ipilimumab and Avelumab in Combination with Intravenous Low-Dose Nivolumab in Patients with Advanced Solid Tumors: A Phase IB Clinical Trial. <i>Vaccines</i> , 2020, 8, 670.	2.1	17
31	Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlations. <i>Journal of Translational Medicine</i> , 2014, 12, 179.	1.8	14
32	Endometrial Cancer Molecular Characterization: The Key to Identifying High-Risk Patients and Defining Guidelines for Clinical Decision-Making?. <i>Cancers</i> , 2021, 13, 3988.	1.7	14
33	Delivery of Tumor-Antigen-Encoding mRNA into Dendritic Cells for Vaccination. <i>Methods in Molecular Biology</i> , 2008, 423, 155-163.	0.4	12
34	Biological Function of PD-L2 and Correlation With Overall Survival in Type II Endometrial Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 538064.	1.3	9
35	In Vitro Validation of Survivin as Target Tumor-associated Antigen for Immunotherapy in Uterine Cancer. <i>Journal of Immunotherapy</i> , 2015, 38, 239-249.	1.2	8
36	Endometrial Stromal Sarcomas: A Revision of Their Potential as Targets for Immunotherapy. <i>Vaccines</i> , 2018, 6, 56.	2.1	7

#	ARTICLE	IF	CITATIONS
37	Dendritic cell therapy for oncology roundtable conference. Journal of Immune Based Therapies and Vaccines, 2011, 9, 1.	2.4	6
38	Dendritic cell immunotherapy in uterine cancer. Human Vaccines and Immunotherapeutics, 2014, 10, 1822-1827.	1.4	6
39	mRNA Electroporation of Dendritic Cells with WT1, Survivin, and TriMix (a Mixture of caTLR4, CD40L,) Tj ETQq1 1 0,784314 rgBT /Over	0.4	5
40	Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?. Cancers, 2021, 13, 2040.	1.7	4
41	Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. Frontiers in Immunology, 2021, 12, 733506.	2.2	4
42	In Vitro Assessment of the Expression and T Cell Immunogenicity of the Tumor-Associated Antigens BORIS, MUC1, hTERT, MAGE-A3 and Sp17 in Uterine Cancer. International Journal of Molecular Sciences, 2016, 17, 1525.	1.8	3
43	Editorial: Approaches to Advance Cancer Vaccines to Clinical Utility. Frontiers in Immunology, 2019, 10, 2032.	2.2	1
44	65MO A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma. Annals of Oncology, 2020, 31, S1443.	0.6	1
45	Acute Drug Effects on the Human Placental Tissue: The Development of a Placental Murine Xenograft Model. Reproductive Sciences, 2018, 25, 1637-1648.	1.1	0
46	EP692â€¦Fulvestrant in gynaecological cancers that are potentially hormone sensitive: the FUCHSia study. , 2019, , .		0
47	Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform. Computational and Structural Biotechnology Journal, 2020, 18, 2217-2227.	1.9	0